Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 128 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Interferon-beta (IFN-beta) Clear all

Conditions: Multiple Sclerosis
Interventions: Diroximel Fumarate, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod; Drug · Biological
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 1,178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Eden Prairie, Minnesota

Conditions: Multiple Sclerosis
Interventions: peginterferon beta-1a, Rebif; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Multiple Sclerosis, Immune System Diseases
Interventions: ocrelizumab; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Choroid Melanoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions: Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Multiple Sclerosis
Interventions: Mycophenolate Mofetil (CellCept); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Farmington Hills, Michigan • Buffalo, New York • Dallas, Texas

Conditions: Multiple Sclerosis
Interventions: IFNbeta-1b; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Not listed
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Foxborough, Massachusetts

Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Duke University; Other
Eligibility: 0 Years to 20 Years
Enrollment: 5,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinosarcoma, Stage IV Uterine Corpus Cancer AJCC v7
Interventions: Biopsy, Computed Tomography, Fluorine F 18 Tetrafluoroborate, Pharmacological Study, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Ruxolitinib Phosphate, Technetium Tc-99m Sodium Pertechnetate, Biospecimen Collection; Procedure · Other · Biological + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multiple Sclerosis
Interventions: Avonex/Zocor; Drug
Lead sponsor: University of North Carolina; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Relapsing Remitting Multiple Sclerosis (RRMS)
Interventions: New Formulation of rebif - human interferon beta-1a, Interferon beta -1b; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Bone Marrow Diseases
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Anifrolumab, Standard of Care; Drug
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 28
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 21 more

Conditions: Multiple Sclerosis
Interventions: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b; Drug
Lead sponsor: Teva Neuroscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Swartz Creek, Michigan • Columbus, Ohio • Carnegie, Pennsylvania

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: Fingolimod, Standard MS DMTs; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,053 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 142
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more

Conditions: Multiple Sclerosis
Interventions: Interferon-beta-1b (BETASERON, BAY 86-5046); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: IFN-β-1a (Rebif®); Drug
Lead sponsor: Waukesha Memorial Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Waukesha, Wisconsin

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Interferon beta 1-a, glatiramer acetate, placebo; Drug · Other
Lead sponsor: Fred Lublin; Other
Eligibility: 18 Years to 60 Years
Enrollment: 1,008 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 67
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more

Conditions: Relapsing Multiple Sclerosis
Interventions: Interferon beta-1a, Ocrelizumab-matching placebo, Ocrelizumab, Interferon beta-1a-matching placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 48
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 43 more

Conditions: Multiple Sclerosis
Interventions: repository corticotropin injection, Saline; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Recurrent Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
Interventions: Aldesleukin, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells, Radiation Therapy, Recombinant Interferon Beta; Biological · Other · Radiation
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis
Interventions: interferon beta 1a, methotrexate, methylprednisolone; Drug
Lead sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: RNS60 125 ml, RNS60 250 ml, Interferon beta 1a; Drug
Lead sponsor: Revalesio Corporation; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

Mechanism of Action of Ocrelizumab in Multiple Sclerosis

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells

Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

EARLY IFNB-1a and Simvastatin Combination Therapy in Clinically Isolated Syndrome Suggestive of Multiple Sclerosis

RNF and Betaseron® Tolerability Study

Cytokine Gene Polymorphisms in Bone Marrow Failure

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis

Therapy Optimization in Multiple Sclerosis (MS)

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector

fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Effect of Adrenocorticotropin Injection With Weekly Interferon Beta in Patients With Relapsing Remitting Multiple Sclerosis (MS)

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.

Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis